AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HIMS

Elshenawy Mohamed sold $226K of HIMS

Elshenawy Mohamed (CTO) sold 7,954 shares of Hims & Hers Health, Inc. (HIMS) at $28.39 ($0.23M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Elshenawy Mohamed
Published Sep 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
high confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect HIMS stock price or investor sentiment.

02

Market read

Routine insider sale with limited market impact.

03

What to watch

The 10b5‑1 plan may have been set months ago; sale does not reflect current sentiment.

Relevance 3/10Novelty 3/10Timing: filing posted Sep 17, 2026 (post‑market)

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$HIMSNeutralHigh confidence
Context

CTO Elshenawy Mohamed sold 7,954 shares for $225.8K via a 10b5‑1 plan.

Expected impact

No significant impact; price likely flat.

Evidence & confidence

Sale size is small relative to total holdings and market cap; insider is offloading via pre‑arranged plan.

Market effects

Sector

None; Hims & Hers operates in telehealth, but insider sale is not sector‑wide.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

If the insider sale signals internal concerns, a short‑term dip could be possible.

Key entities

  • Officer
    Elshenawy Mohamed

    Chief Technology Officer of Hims & Hers Health, Inc.

  • Company
    Hims & Hers Health, Inc.

    Telehealth provider listed on NASDAQ under ticker HIMS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

finance.yahoo.com
$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.

claimsjournal.com